Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

OSAKA, Japan & CAMBRIDGE, Mass. & PASADENA, Calif.--(BUSINESS WIRE)--Takeda and Arrowhead announce Phase 2 results of fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.

Click to view original post